Scm like with four mbt domains 1Genealiases: RU1 · SFMBT · hSFMBT
Q-omics provides the consensus-scored SFMBT1 profile across patient tissues and cancer cell-line models. SFMBT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SFMBT1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, SFMBT1 RNA expression shows 20,072 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where SFMBT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFMBT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFMBT1 survival associations across molecular data types. SFMBT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFMBT1 RNA expression–survival associations across cancer types. High SFMBT1 expression shows unfavorable associations in MESO, ACC and LGG, but favorable associations in BRCA, KIRC and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SFMBT1 RNA expression.
This table summarizes SFMBT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SFMBT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFMBT1 shows lower tumor expression in THCA and higher tumor expression in LIHC, STAD, BLCA, COAD and UCEC. The THCA box plot shows higher SFMBT1 RNA expression in normal versus tumor tissue (log2 FC = −1.140, t-test p < 0.001).
This table shows molecular features associated with SFMBT1 in patient tissues and cancer cell lines. In patient samples, SFMBT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SFMBT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
